Trade Exagen Inc. - XGN CFD

Exagen Inc. Company profile

About Exagen Inc

Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. The Company's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases ( CTD) and Systemic lupus erythematosus (SLE). Its other diagnostic testing includes AVISE Lupus and AVISE antiphospholipid syndrome (APS). Its Prognosis tests include AVISE systemic lupus erythematosus (SLE) Prognostic, AVISE Anti- carbamylated proteins (CarP) and AVISE Platelet-bound C4d (PC4d). Its monitoring tests include AVISE SLE Monitor, AVISE methotrexate (MTX) and AVISE hydroxychloroquine (HCQ).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Exagen Inc revenues increased 22% to $35.6M. Net loss increased 50% to $19.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, general & administrative exp increase from $200K to $28.5M (expense), Other income / (expense), net decrease of 100% to $1K (income).